On November 6, Hims & Hers Health Inc. rose 6.59% in Regular Trading, trading at $25.2289 per share, with turnover of $41.0189 million.

The main catalyst was a newly announced agreement with Eli Lilly to expand patient access to Zepbound and Foundayo through the Hims & Hers platform, giving eligible self-pay patients access to Lilly’s standard cash prices without leaving the platform.

Under the agreement, users can complete consultations, obtain prescriptions from licensed providers, and order delivery directly on the platform. The news also comes ahead of the company’s November 9 earnings release, where consensus expects quarterly revenue of $893 million, up 53.88% year over year, and EPS of $0.07, helping offset recent pressure tied to FTC litigation and subscription billing disputes.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)